NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Inhalon Biopharma Inc.

Inhalon Biopharma Inc.

Private
Morrisville, North CarolinaHealthcare & Life Scienceshttps://www.inhalon.com/

Last Round

Grant

Nov 15, 2023

Total Funding Raised

$21.3M

Company Overview

Inhalon Biopharma Inc. is a clinical-stage biotechnology company developing inhaled antibody treatments for acute respiratory infections such as RSV, influenza, and SARS-CoV-2.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Defense Tech

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

inhaled therapeuticsmuco-trapping platformmonoclonal antibodyrespiratory infectionsdrug delivery technologynebulized therapybiotechtest-to-treatclinical-stage biopharmadefense healthlung deliveryself-administered medicinebiodefensedrug developmentgovernment contracting

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Inhalon Biopharma Inc. Comparables

Compare Inhalon Biopharma Inc. with similar companies based on industry and business-model similarity.

Inhalon Biopharma Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pulmocide
76%
Mucommune, LLC
73%
Synairgen plc
70%

Inhalon Biopharma Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 15, 2023
Series AJun 30, 2022
GrantMay 26, 2021
SeedAug 26, 2020
SeedMar 20, 2019

Key People

Founding team and executive leadership

John Whelan

President And CEO

Executive Team

Inhalon Biopharma Inc. Investors

Notable investors and investment history

Inhalon Biopharma Inc. investors
InvestorRounds
Thiel FoundationSeed
Berkeley Catalyst FundSeries A, Seed
JSR Life SciencesSeries A
Life Science AngelsSeries A, Seed
Band of AngelsSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 3, 2025

    Human challenge trial initiated for RSV treatment.

Inhalon Biopharma Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Inhalon Biopharma Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Inhalon Biopharma Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersMorrisville, North Carolina
Employee Range9
Year Founded2018
Last FundingNov 15, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.